Last reviewed · How we verify
Ticagrelor or Prasugrel
Ticagrelor or Prasugrel is a P2Y12 receptor antagonist Small molecule drug developed by St. Antonius Hospital. It is currently FDA-approved for Acute coronary syndrome (ACS) including unstable angina, NSTEMI, and STEMI, Secondary prevention after percutaneous coronary intervention (PCI), Reduction of thrombotic cardiovascular events in patients with established coronary artery disease. Also known as: Brilinta, Prasuvas.
Both ticagrelor and prasugrel are P2Y12 receptor antagonists that inhibit platelet aggregation by blocking ADP-mediated platelet activation.
Prasugrel is a small molecule used to treat conditions such as myocardial infarction, atrial fibrillation, and platelet dysfunction. It is used in conjunction with other medications, including edoxaban and vitamin K antagonists, in patients undergoing percutaneous coronary intervention.
At a glance
| Generic name | Ticagrelor or Prasugrel |
|---|---|
| Also known as | Brilinta, Prasuvas |
| Sponsor | St. Antonius Hospital |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
These drugs bind irreversibly (prasugrel) or reversibly (ticagrelor) to the P2Y12 adenosine diphosphate receptor on platelet surfaces, preventing platelet clumping and thrombus formation. They are used as antiplatelet agents in acute coronary syndromes and after percutaneous coronary intervention to reduce cardiovascular events.
Approved indications
- Acute coronary syndrome (ACS) including unstable angina, NSTEMI, and STEMI
- Secondary prevention after percutaneous coronary intervention (PCI)
- Reduction of thrombotic cardiovascular events in patients with established coronary artery disease
Common side effects
- Bleeding (major and minor)
- Dyspnea (ticagrelor)
- Bradycardia (ticagrelor)
- Thrombotic thrombocytopenic purpura (prasugrel)
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- ARCANGELO (itAlian pRospective Study on CANGrELOr)
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (PHASE4)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor or Prasugrel CI brief — competitive landscape report
- Ticagrelor or Prasugrel updates RSS · CI watch RSS
- St. Antonius Hospital portfolio CI
Frequently asked questions about Ticagrelor or Prasugrel
What is Ticagrelor or Prasugrel?
How does Ticagrelor or Prasugrel work?
What is Ticagrelor or Prasugrel used for?
Who makes Ticagrelor or Prasugrel?
Is Ticagrelor or Prasugrel also known as anything else?
What drug class is Ticagrelor or Prasugrel in?
What development phase is Ticagrelor or Prasugrel in?
What are the side effects of Ticagrelor or Prasugrel?
What does Ticagrelor or Prasugrel target?
Related
- Drug class: All P2Y12 receptor antagonist drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: St. Antonius Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (ACS) including unstable angina, NSTEMI, and STEMI
- Indication: Drugs for Secondary prevention after percutaneous coronary intervention (PCI)
- Indication: Drugs for Reduction of thrombotic cardiovascular events in patients with established coronary artery disease
- Also known as: Brilinta, Prasuvas
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing